某三甲医院2017年神经内科辅助用药分析
|
摘要
目的促进临床合理用药,为医院药品调控提供参考。方法利用医院信息管理系统,检索2017年神经内科辅助用药的数据,采用用药金额、用药频度(DDDs)等指标对用药进行统计与分析。结果销售金额排在前10位的均为注射剂,以脑血管类药为主,位居首位的为前列地尔注射液; DDDs居首位的为奥美拉唑肠溶片。结论该院神经内科临床用药以活化脑血管神经药和护胃药为主,奥美拉唑肠溶片DDDs最高,单品用药仍存在不合理现象,应加强药品的管理和用药指导,规范临床用药。
Objective To promote rational drug use in the clinic and provide reference for drug control in the hospital. Methods The data of adjuvant drugs used in the Department of Neurology in 2017 were retrieved by the hospital information management system,the sales amounts and DDDs were used to make statistics and analysis of drug use. Results The top 10 sales amounts were injections,mainly cerebrovascular drugs, Alprostadil Injection ranked first. Omeprazole Enteric-Coated Tablets ranked first for DDDs. Conclusion Activating cerebrovascular nerve drugs and stomach-protecting drugs are the main clinical medicines in the Department of Neurology in our hospital. The DDDs of Omeprazole Enteric-Coated Tablets is the highest. There are still unreasonable phenomena in single drug use.Drug management and medication guidance should be strengthened to standardize clinical medication.
Objective To promote rational drug use in the clinic and provide reference for drug control in the hospital. Methods The data of adjuvant drugs used in the Department of Neurology in 2017 were retrieved by the hospital information management system,the sales amounts and DDDs were used to make statistics and analysis of drug use. Results The top 10 sales amounts were injections,mainly cerebrovascular drugs, Alprostadil Injection ranked first. Omeprazole Enteric-Coated Tablets ranked first for DDDs. Conclusion Activating cerebrovascular nerve drugs and stomach-protecting drugs are the main clinical medicines in the Department of Neurology in our hospital. The DDDs of Omeprazole Enteric-Coated Tablets is the highest. There are still unreasonable phenomena in single drug use.Drug management and medication guidance should be strengthened to standardize clinical medication.
引文
[1]赖延锦.浅谈辅助用药在临床药物治疗中的价值[J].中国医药指南,2014,12(13):389-390.
[2]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:704.
[3]国家药典委员会.中国药典·临床用药须知[M].北京:中国医药科技出版社,2011:89-372.
[4]李虹君. 2008~2010年我院抗精神病药利用分析[J].药物流行病学杂志,2011,20(7):362-363.
[5]胡晋红.使用医院药学[M].上海:上海科学技术出版社,2000:611-615.
[6]段若竹,吴剑波.免疫增强剂的研究应用及展望[J].国外医药:抗生素分册,2006,27(2):54-57.
[7]胡洪涛,霍墨菲,孙瑞华.前列地尔注射液与常规治疗对缺血性卒中疗效比较的Meta分析[J].中华老年医学杂志,2012,31(7):562.
[8] MALYKH AG,SADAIE MR. Piracetam and piracetam-like drugs:from basic science to novel clinical applications to CNS disorders[J]. Drugs,2010,70(3):287-312.
[9] NIXON GM,BROUILETTE RT. Sleep 8 paediatric apnoea[J].Thorax,2005,60(6):511-516.
[10]张兆辉,彭晓琴,何国厚.奥拉西坦改善急性脑卒中患者认知功能疗效的Meta分析[J].医学综述,2014,20(22):4170-4173.
[11] YANG Z,WU YL. Edaravone,an ethical brain protecting agent for acute cerebral infarction[J]. Chin New Drugs J(in Chinese),2002,11(12):911-913.
[12]李群.应激性溃疡防治建议[J].中华医学杂志,2002,82(14):1000-1001.
[13]代红梅.奥美拉唑预防脑卒中并发应激性溃疡疗效观察[J].中国现代药物应用,2011,5(9):57.
[14] Antithrombotic Trialists'Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J]. BMJ,2002,324(7329):71-86.
[15] COOK DJ,REEVE BK,GUYATT GH,et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses[J]. JAMA,1996,275(4):308-314.
[16]李兆申.重视应激性溃疡的规范化防治[J].世界华人消化杂志,2005,13(22):2637-2639.
[17] LIN KJ,HERNANDEZ-DIAZ S,GARCIA RODRIGUEZ LA.Acid suppressants reduce risk of gastrointestional bleeding in patients on antithrombotic or anti-inflammatory therapy[J].Gastroenterology,2011,141(1):71-79.
[18] CHEN J,YUAN YC,LEONTIADIS GI,et al. Recent safety concems with proton pump inhibitors[J]. J Clin Gastronenterol,2012,46(2):93-114.
[19]沈志伟.抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版)[J].中华内科杂志,2013,52(3):266-267.
[2]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:704.
[3]国家药典委员会.中国药典·临床用药须知[M].北京:中国医药科技出版社,2011:89-372.
[4]李虹君. 2008~2010年我院抗精神病药利用分析[J].药物流行病学杂志,2011,20(7):362-363.
[5]胡晋红.使用医院药学[M].上海:上海科学技术出版社,2000:611-615.
[6]段若竹,吴剑波.免疫增强剂的研究应用及展望[J].国外医药:抗生素分册,2006,27(2):54-57.
[7]胡洪涛,霍墨菲,孙瑞华.前列地尔注射液与常规治疗对缺血性卒中疗效比较的Meta分析[J].中华老年医学杂志,2012,31(7):562.
[8] MALYKH AG,SADAIE MR. Piracetam and piracetam-like drugs:from basic science to novel clinical applications to CNS disorders[J]. Drugs,2010,70(3):287-312.
[9] NIXON GM,BROUILETTE RT. Sleep 8 paediatric apnoea[J].Thorax,2005,60(6):511-516.
[10]张兆辉,彭晓琴,何国厚.奥拉西坦改善急性脑卒中患者认知功能疗效的Meta分析[J].医学综述,2014,20(22):4170-4173.
[11] YANG Z,WU YL. Edaravone,an ethical brain protecting agent for acute cerebral infarction[J]. Chin New Drugs J(in Chinese),2002,11(12):911-913.
[12]李群.应激性溃疡防治建议[J].中华医学杂志,2002,82(14):1000-1001.
[13]代红梅.奥美拉唑预防脑卒中并发应激性溃疡疗效观察[J].中国现代药物应用,2011,5(9):57.
[14] Antithrombotic Trialists'Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J]. BMJ,2002,324(7329):71-86.
[15] COOK DJ,REEVE BK,GUYATT GH,et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses[J]. JAMA,1996,275(4):308-314.
[16]李兆申.重视应激性溃疡的规范化防治[J].世界华人消化杂志,2005,13(22):2637-2639.
[17] LIN KJ,HERNANDEZ-DIAZ S,GARCIA RODRIGUEZ LA.Acid suppressants reduce risk of gastrointestional bleeding in patients on antithrombotic or anti-inflammatory therapy[J].Gastroenterology,2011,141(1):71-79.
[18] CHEN J,YUAN YC,LEONTIADIS GI,et al. Recent safety concems with proton pump inhibitors[J]. J Clin Gastronenterol,2012,46(2):93-114.
[19]沈志伟.抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版)[J].中华内科杂志,2013,52(3):266-267.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |